Balance Sheet

v3.8.0.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 8,962,472 $ 9,763,067
Accounts receivable 5,399 14,833
Prepaid expenses and other current assets 1,652,740 1,967,257
Total Current Assets 10,620,611 11,745,157
Property and Equipment, net 661,957 286,891
Other Assets    
Restricted cash 1,170 2,292
In-process R&D 5,866,000 5,866,000
Goodwill 2,189,338 2,189,338
Deposits 79,219 69,798
Deferred financing costs 40,173 30,000
Total Other Assets 8,175,900 8,157,428
Total Assets 19,458,468 20,189,476
Current Liabilities    
Accounts payable 1,701,623 1,033,680
Deferred revenue 6,273,861 7,026,388
Accrued expenses and other liabilities 1,558,661 2,276,431
Total Current Liabilities 9,534,145 10,336,499
Long Term Liabilities    
Other long term liabilities 160,942 160,559
Deferred tax liability 1,302,220 1,302,220
Contingent consideration 2,620,407 2,609,289
Total Liabilities 13,617,714 14,408,567
Commitments and Contingencies
Stockholders' Equity    
Common stock, $.0002 par value; 100,000,000 shares authorized, 5,663,919 and 4,200,310 shares issued and outstanding at March 31, 2018 (unaudited) and December 31, 2017, respectively 1,133 840
Additional paid-in capital 80,153,716 76,382,262
Accumulated deficit (72,373,092) (68,846,326)
Accumulated other comprehensive loss (144,700) (166,025)
Total Stockholders' Equity-Heat Biologics, Inc. 7,637,057 7,370,751
Non-Controlling Interest (1,796,303) (1,589,842)
Total Stockholders' Equity 5,840,754 5,780,909
Total Liabilities and Stockholders' Equity $ 19,458,468 $ 20,189,476

Source